2 Jun 2025 • A new study has found that tirzepatide, a GLP-1 receptor agonist, delivers similar overall clinical outcomes as bariatric metabolic surgery (BMS) in adults with obstructive sleep apnea (OSA) and obesity.

In a matched cohort of 10,269 patients per group, no significant differences were observed in all-cause mortality (HR 0.90) or major adverse cardiovascular events (HR 1.16), with a composite outcome HR of 0.87. Notably, tirzepatide was associated with a 40% lower risk of major adverse kidney events (HR 0.60) compared to surgery.

These findings position tirzepatide as a viable non-surgical option, especially for patients at risk of renal complications.

Source: Diabetes Research & Clinical Practice | Read Full Story